GlassScriptPhysician profile
Dana M Teller
NPI 1295154607
$2,608.23
in general payments reported to CMS, 2019-2025
38 companies · $432 in 2025
The $432 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $409 · 2021: $326 · 2022: $441 · 2023: $281 · 2024: $562 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,200 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,200.11 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $357.00 | 2019-2020 | |
| Astellas Pharma US INC | $259.84 | 2023-2024 | Veozah |
| Mayne Pharma Commercial LLC | $227.69 | 2021-2025 | |
| Coopersurgical, INC. | $168.54 | 2020-2024 | Paragard T 380a, Paragard T 380a |
| Abbvie INC. | $145.45 | 2019-2022 | |
| Biogen, INC. | $136.56 | 2024-2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $131.01 | 2021-2025 | Aptima |
| Amgen INC. | $101.81 | 2022-2025 | Evenity, Prolia, Prolia |
| Exact Sciences Corporation | $94.54 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $86.02 | 2021-2025 | |
| Channel Medsystems, INC. | $85.95 | 2022-2023 | |
| Organon LLC | $68.41 | 2022-2025 | Nexplanon |
| Pfizer INC. | $66.23 | 2024 | |
| Lupin INC. | $56.86 | 2020-2021 | |
| Myovant Sciences INC. | $55.41 | 2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $47.09 | 2023-2025 | Myfembree |
| Avion Pharmaceuticals | $44.30 | 2020-2021 | |
| Shield Therapeutics INC | $43.90 | 2022 | |
| Exeltis, USA INC. | $43.31 | 2020-2021 | |
| Aspira Women'S Health INC | $36.91 | 2022-2023 | Ova1 |
| Daiichi Sankyo INC. | $34.81 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.73 | 2022 | |
| Ethicon US, LLC | $32.15 | 2025 | Stratafix, Evarrest |
| Millicent US INC | $31.66 | 2024-2025 | Femlyv, Intrarosa, Femring |
| Evofem Biosciences, INC. | $28.49 | 2021 | |
| Merck Sharp & Dohme LLC | $26.60 | 2019 | |
| Becton, Dickinson and Company | $18.20 | 2025 | Bd Onclarity |
| Lilly USA, LLC | $15.63 | 2022 | |
| Agile Therapeutics, INC. | $15.00 | 2021 | |
| Seqirus USA INC | $14.78 | 2024 | Flucelvax |
| Therapeuticsmd, INC. | $14.77 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $14.70 | 2021 | |
| Vertical Pharmaceuticals, LLC | $14.13 | 2019 | |
| Innovation Technologies INC | $13.74 | 2025 | Irrisept |
| Mylan Pharmaceuticals INC. | $13.13 | 2021 | |
| Alexion Pharmaceuticals, INC. | $12.00 | 2019 | |
| Allergan, INC. | $11.55 | 2019 | |
| Meditrina | $5.33 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Teller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.